• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Essential Pharma acquires European rights to Colobreathe from Teva

    GLOBENEWSWIRE

    Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb®

    PRESS RELEASE

    EU drug regulators review use of last-resort antibiotic in farming

    REUTERS

    Xellia`s Generic Colistimethate Sodium (Eq 150Mg Base/Vial) Approved in US For Bacterial Infections

    FDA

    Heritage Pharmaceuticals, Inc., Ongoing Class II recall of Colistimethate for Injection USP, 150 mg per vial, Rx Only, Manufactured by: Emcure Pharmaceuticals Ltd., Hinjwadi, Pune, India Manufactured for: Heritage Pharmaceuticals Inc. NDC 23155-193-31 because of Lack of Assurance of Sterility: Firm is recalling two injectable products due to concerns with quality control processes.

    FDA

    Heritage Pharmaceuticals Initiates a Nationwide Voluntary Recall of Colistimethate for Injection USP, 150 mg and Rifampin for Injection USP, 600 mg/vial Due to a Lack of Sterility Assurance

    USFDA

    Sagent Pharmaceuticals Announces the Launch of Colistimethate for Injection, USP

    SAGENT PHARMACEUTICALS

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.